FDA OKs Later-Line Breast Cancer Drug
Approved for HER2-positive patients following two prior anti-HER2-based regimens
Related Articles
Massachusetts Cuts Residency Requirement for IMGs
IMGs must work 3 years in underserved areas before being fully licensed
FTC Settles With Private Equity Firm Over Anesthesia Investments
‘We consider this a definite victory,’ physician says
The Impact of Climate Change on Atopic Dermatitis
Many of the hazardous natural conditions exacerbated by climate change could have a negative impact on patients with atopic dermatitis (AD). The recent review, conducted…
Storm-Chasing Doctor Makes Annual Trip to ‘Tornado Alley’
‘Tornadoes really are incredible beasts,’ says Colorado hospitalist
FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen
Drug is approved in combination with fludarabine
Trump Administration Forces NIH Meeting Cancellations
Researchers and healthcare professionals express concern over the potential impact
No Clear Winner in SGLT2 Showdown for Cardiovascular Disease
Real-world data on empagliflozin, canagliflozin, and dapagliflozin
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
An integrated intervention had the greatest impact in a randomized trial
